Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who’s Hired? O’Brien To Replace Richards As Mayne Pharma CEO

Plus Hikma Appoints New Board Members And Mallinckrodt Welcomes New CCO

Executive Summary

Mayne Pharma has announced the appointment of pharma industry veteran Shawn O’Brien as CEO, replacing outgoing delegate Scott Richards. Plus, Hikma has appointed two new female board members, in line with gender diversity targets set by the UK Financial Conduct Authority.

You may also be interested in...



Mayne Completes Divestment Of US Generics To Dr Reddy’s

Mayne Pharma and Dr Reddy’s have announced the completion of a deal that will see the Indian company take over the Australian firm’s US generics business.

Dr Reddy’s Swallows Up Mayne’s US Generics Portfolio For $90m+

Dr Reddy’s has struck a deal to pay at least $90m for the US prescription generics portfolio of Mayne Pharma. The transaction covers products including Mayne’s recently-launched rival to NuvaRing.

India’s Piramal Pharma Rings The Bell On Domestic Stock Exchange Listings

Piramal Pharma is “embarking on a new journey as a focused pharma entity,” as it seeks to “identify and secure inorganic and organic growth opportunities to generate consistent shareholder value.”

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152207

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel